ArticleScientific reports2026
Anti-fibrotic effects of evogliptin in fibroblasts derived from post-burn hypertrophic scars.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hypertrophic scar (HTS) frequently occurs after burn injury, characterized by persistent fibroblast activation, overexpression of α-smooth muscle actin (αSMA) and extracellular matrix (ECM) components. Complete scarless regeneration remains incompletely understood. Dipeptidyl peptidase-4 (DPP4) is a cell-surface serine protease, its inhibitors (DPP4i) have been associated with fibrosis. However, the functional role of evogliptin in HTS formation remains unclear. This investigated its effects on fibrosis markers in hypertrophic scar fibroblasts (HTSFs). Human normal fibroblasts (HNFs) and HTSFs were isolated from normal skin and post-burn HTS tissues. DPP4 expression in HTS and normal skin tissues was detected using immunocytochemistry. mRNA and protein expression levels were determined via quantitative real-time polymerase chain reaction and western blot, respectively. Evogliptin treatment in HTSFs and HNFs treated with transforming growth factor-beta 1 (TGF-β) both inhibited the expression of differentiation markers, including αSMA, TGF-β1, YAP1, TEAD1, and CTGF, thereby reducing fibroblast activation; ECM components, including type Ⅰ collagen, type Ⅲ collagen, and fibronectin; epithelial-mesenchymal transition (EMT) markers, including snail1, slug, twist1, vimentin, and n-cadherin; and TGF-β-mediated signaling molecules, including SMAD2, SMAD3, TAK1, ERK, p38, JNK, AKT, and STAT3. Our results demonstrated that evogliptin exerts its anti-fibrotic activity by inhibiting fibroblast activation, EMT, and ECM synthesis in HTSFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.